2.4.1. Inclusion criteria.
sore throat, diarrhea, cough, tiredness, headache, nausea,, shivering, chills, aches, shortness of breath
SORE THROAT, TASTE DISORDER, SMELL DISORDER
Patients must be capable of providing signed informed consent/assent and must be ≥12 years and <70 years of age at the time of providing informed consent/assent. All patients must have been diagnosed as SARS-CoV-2–positive within 120 hours before randomization via either a nucleic acid detection test using a nasopharyngeal swab, nasal swab, or saliva (qualitative/quantitative reverse transcription-polymerase chain reaction [RT-PCR] test or an isothermal nucleic acid amplification method [e.g., the loop-mediated isothermal amplification method or the transcription-mediated amplification method]), a quantitative antigen test using a nasopharyngeal swab, nasal swab, or saliva, or a qualitative antigen test using a nasopharyngeal or nasal swab; have a time from COVID-19 onset to randomization of ≤120 hours (when at least 1 of the 14 symptoms occurs: low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, stuffy or runny nose, sore throat, cough, shortness of breath, nausea, vomiting, diarrhea, smell disorder, and taste disorder); and have at least 1 moderate symptom (COVID-19 symptom score 2; Supplemental Table 1, 